Anthony Marucci, Celldex CEO
February 28, 2023 10:46 AM EST
R&D

Celldex flesh­es out case for Xo­lair chal­lenger in chron­ic hives

Paul Schloesser

Associate Editor

Celldex Ther­a­peu­tics is de­tail­ing more da­ta from a Phase I tri­al, close to eight months af­ter shar­ing ini­tial re­spons­es from an in­ter­im analy­sis.

The New …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times